Failure of Anti-HIV Gel Shows Difficulty of Prevention

Updated on

A vaginal gel containing Gilead Sciences Inc.’s HIV drug Viread, which has shown promise at preventing infections in past tests, was ineffective when used by at-risk women in South Africa, a study found.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.